Clinical Trial Update: A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. [Phase 2]

View source ↗

Summary

Phase II trial evaluating tislelizumab with platinum doublet neoadjuvant therapy for resectable locally advanced oral squamous cell carcinoma to improve mandibu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Xuekui Liu | Conditions: Oral Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN